PRODUCTS
Product Name | Strength | Image (not to scale) | Pack Size | NDC # | RLD / Brand Name | TE Rating | Therapeutic Category |
---|---|---|---|---|---|---|---|
Flucytosine Capsules USP | 250 mg |
|
100 |
43386-771-01 |
Ancobon® |
AB |
Antifungal |
Fluocinonide Topical Solution USP | 0.05% |
|
20 mL |
43386-026-02 |
Lidex® |
AT |
Corticosteroid |
Fluoxetine Tablets USP | 10mg |
|
30 |
68180-998-01 |
Prozac® |
AB |
Anti-depressant |
Fluoxetine Tablets USP | 60mg |
|
30 |
68180-997-06 |
Fluoxetine Tablets |
AB |
Anti-depressant |
Formoterol Fumarate Inhalation Solution | 20mcg/2mL |
|
30 UD Vials |
70748-261-30 |
Perforomist® |
AN |
Long-acting beta agonists (LABAs)/ Bronchodilator |
Fosaprepitant Dimeglumine for Injection | 150mg |
|
5mL single-dose vial |
68180-690-01 |
Emend® |
AP |
Antiemetic |
Fyavolv™ | 0.5mg/0.0025mg |
|
28 x 3 |
68180-827-09 |
FemHRT® |
AB |
Hormone Replacement Therapy |
Ganirelix Acetate Injection | 250mcg/0.5mL |
|
(1) 250mcg single-dose pre-filled syringe |
70748-274-01 |
Ganirelix Acetate Injection |
AP |
Competitive gonadotropin-releasing hormone antagonist (GnRH antagonist) |
GaviLAX (PEG3350) Powder for Oral Solution | 17gm/scoopful |
|
238g |
43386-312-14 |
MiraLAX® |
AA |
Laxative |
GaviLyteâ„¢ – C | 240 -5.84-2.98-6.72-22.72gm |
|
4 L |
43386-060-19 |
Colyte® |
AA |
Hyperosmotic |
GaviLyteâ„¢ – G | 236-5.86-2.97-6.74-22.74 gm |
|
4 L |
43386-090-19 |
GoLYTELY® |
AA |
Hyperosmotic |
GaviLyteâ„¢-N | 420-111.20-1.48-5.72 gm |
|
4 L |
43386-050-19 |
NuLYTELY® |
AA |
Hyperosmotic |
*All registered trademarks are the property of their respective owners. These products are intended for U.S. residents only.